1 Exhibit 10.4 LOAN AND SECURITY AGREEMENT THIS AGREEMENT ("Agreement") made this _____ day of March, 2000, between , a Florida corporation, with its chief executive office and principal place of business at , (hereinafter "Dealer"), and AFFORDABLE...Loan and Security Agreement • April 7th, 2000 • First Capital Resources Com Inc • Blank checks • Florida
RECITALS:Asset Purchase Agreement • April 7th, 2000 • First Capital Resources Com Inc • Blank checks • Florida
AGREEMENTVoting Agreement • June 2nd, 2006 • Innovate Oncology, Inc. • Non-operating establishments • New York
RECITALSVoting Agreement • February 7th, 2006 • Innovate Oncology, Inc. • Non-operating establishments • New York
STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 16th, 1999 • Jackal Industries Inc • Blank checks • Nevada
RECITALSVoting Agreement • February 7th, 2006 • Innovate Oncology, Inc. • Non-operating establishments • New York
EXHIBIT 10.2 EMPLOYMENT AGREEMENT AGREEMENT dated as of May 26th, 2006, between INNOVATE ONCOLOGY, INC., a Nevada corporation ("COMPANY"), and CHRISTOPHER NOWERS, an individual ("EXECUTIVE"). Company desires to employ Executive, and Executive desires...Employment Agreement • June 2nd, 2006 • Innovate Oncology, Inc. • Non-operating establishments • California
Exhibit 10.1 SHARE EXCHANGE AGREEMENT dated as of January 31, 2006Share Exchange Agreement • February 7th, 2006 • Innovate Oncology, Inc. • Non-operating establishments • New York
EMPLOYMENT AGREEMENTEmployment Agreement • July 17th, 2007 • Avantogen Oncology, Inc. • Non-operating establishments • California
AGREEMENT dated as of July 1, 2007, between AVANTOGEN ONCOLOGY, INC., a Nevada corporation (“Company”), and MICHAEL HILLMEYER, an individual (“Executive”).
SECURITY AGREEMENTSecurity Agreement • October 18th, 2006 • Avantogen Oncology, Inc. • Non-operating establishments • California
SECURITY AGREEMENT dated this 12th day of October, 2006 by and between AVANTOGEN ONCOLOGY, INC., a Nevada corporation with offices at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (the “Company”), and CHOPIN OPUS ONE, L.P., a Cayman Islands limited partnership with offices c/o Chopin Capital Partners, LLC, 2150 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (the “Secured Party”).
AMENDMENT TO LOAN AGREEMENTLoan Agreement • December 18th, 2006 • Avantogen Oncology, Inc. • Non-operating establishments
AMENDMENT dated as of December 12, 2006, to the Loan Agreement dated as of October 12, 2006 (the “Loan Agreement), between AVANTOGEN ONCOLOGY, INC., a Delaware corporation, as “Borrower”, and CHOPIN OPUS ONE L.P., a Cayman Islands limited partnership, as Lender”.
LOAN AGREEMENTLoan Agreement • October 18th, 2006 • Avantogen Oncology, Inc. • Non-operating establishments • California
THIS LOAN AGREEMENT (this “Agreement”) made this 12th day of October, 2006 by and between AVANTOGEN ONCOLOGY, INC., a Nevada corporation with offices at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Borrower”) and CHOPIN OPUS ONE, L.P., a Cayman Islands limited partnership with offices c/o Chopin Capital Partners, LLC, 2150 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Lender”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 23rd, 2006 • Avantogen Oncology, Inc. • Non-operating establishments • California
AGREEMENT dated as of July 17, 2006, between AVANTOGEN ONCOLOGY, INC., a Nevada corporation (“Company”), and ANGELA BRONOW DAVANZO, an individual (“Executive”).
EXHIBIT 99.1 AVANTOGEN LOGO INNOVATE ONCOLOGY LOGO AVANTOGEN AND INNOVATE COMPLETE MERGER OF KEY ONCOLOGY PROGRAM MAY 26, 2006 - Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate";...Innovate Oncology, Inc. • June 2nd, 2006 • Non-operating establishments
MAY 26, 2006 - Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate"; IOVO:OTCBB), New York, closed today on the Definitive Agreement combining their oncology businesses, that was executed and announced by the companies on February 1, 2006. Pursuant to that agreement, Avantogen transferred to Innovate the 50% of Resistys, Inc., not already owned by Innovate, and as a result, Innovate will control 100% of the North American marketing rights for product sales of RP101, a promising chemoresistance inhibitor. The transaction had previously been approved by a majority of both Innovate and Avantogen shareholders.
ARTICLE 1 DEFINITIONSParticipation Agreement • April 7th, 2000 • First Capital Resources Com Inc • Blank checks • Florida
TERMINATION OF AGREEMENT AND RELEASESTermination of Agreement and Releases • November 13th, 2006 • Avantogen Oncology, Inc. • Non-operating establishments • California
AGREEMENT dated as of November 6, 2006, between SUPRATEK PHARMA, INC. (“SPI”), on the one hand, and AVANTOGEN ONCOLOGY, INC., formerly known as Innovate Oncology, Inc. (“AOI”), and GARDANT PHARMACEUTICALS INC., formerly known as Bioaccelerate Holdings Inc. (“GDT”), severally, on the other hand.
TERMINATION OF AGREEMENT AND RELEASESTermination of Agreement and Releases • May 31st, 2007 • Avantogen Oncology, Inc. • Non-operating establishments • California
This AGREEMENT (this “Agreement”), dated as of May 18, 2007, is entered into between PROSTAGENICS LLC, a New York limited liability company (“Prostagenics”), on the one hand, and AVANTOGEN ONCOLOGY, INC., a Nevada corporation formerly known as Innovate Oncology, Inc. (“AOI”), on the other hand.
